AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
Retrieved on:
Wednesday, September 23, 2020
Two secondary endpoints, Alzheimers Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimers Disease Cooperative Study Group Activities of Daily Living Inventory (ADCS-ADL) were also not met.
Key Points:
- Two secondary endpoints, Alzheimers Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimers Disease Cooperative Study Group Activities of Daily Living Inventory (ADCS-ADL) were also not met.
- Additional data analyses are ongoing and Genentech plans to present the results from TAURIEL at an upcoming medical congress.
- The Phase 2 TAURIEL study of semorinemab is a 73-week, double-blind, placebo-controlled trial to determine if it can slow the rate of clinical decline in early (prodromal to mild) AD.
- Two secondary endpoints, Alzheimers Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimers Disease Cooperative Study Group Activities of Daily Living Inventory (ADCS-ADL) also were not met.